For its first fiscal quarter (ending March 31), Medifast Inc. (NYSE: MED) has reported a -79% decline in E.P.S. from $3.68 a year ago to $0.76 in the current quarter. This performance was $-0.03 short of the consensus estimate of $0.79. E.P.S. were $6.21 for the latest four quarters through March 31 versus $12.85 for the same period a year ago — a decline of -52%.
Recent Price Action
Medifast Inc. (NYSE: MED) stock closed at $35.51 on 4/29/24 after a very large increase of 5.3%. Moreover, this advance was accompanied by unusually high trading volume at 153% of normal. The stock has risen 9.5% during the last week but has been extremely weak relative to the market over the last nine months.
Current PriceTarget Research Rating
MED is expected to continue to be an important Value Builder reflecting capital returns that are forecasted to exceed the cost of capital.
Medifast has a current Value Trend Rating of F (Lowest Rating). The Value Trend Rating reflects consistent signals from PTR’s two proprietary measures of a stock’s attractiveness. Medifast has a poor Appreciation Score of 29 and a very low Power Rating of 1, leading to the Lowest Value Trend Rating.
Rating Review
In light of this discouraging new earnings information we are reviewing our current Overall Rating of F. This review will be completed in the next several days.
Be the first to comment